Business Context and Reporting Period
Company: Neurogene Inc. (NGNE)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Neurogene is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. Its primary focus is NGN-401, a gene therapy utilizing the proprietary EXACT platform for the treatment of Rett syndrome. The company operates a fully operational cGMP manufacturing facility in Houston, Texas.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0.9 million |
| Net Loss | $(90.4) million | $(75.1) million |
| Research & Development Expenses | $75.0 million | $60.9 million |
| General & Administrative Expenses | $28.3 million | $22.6 million |
| Cash, Cash Equivalents & Short-term Investments | $269.0 million | $312.4 million |
| Accumulated Deficit | $(352.6) million | $(262.3) million |
| Net Cash Used in Operating Activities | $(77.2) million | $(70.6) million |
Note: Revenue in 2024 consisted of licensing revenue from legacy Neoleukin assets. No product revenue has been generated.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by $15.2 million (20.2%) year-over-year, driven primarily by higher operating expenses.
- R&D Expense Growth: R&D expenses increased by $14.1 million. This was largely due to a $13.7 million increase in costs for the Rett syndrome program (NGN-401), offset by a $4.4 million decrease in the Batten disease program (NGN-101) following its de-prioritization.
- Capital Raises: The company raised $30.1 million in net proceeds through an At-The-Market (ATM) offering in 2025. In late 2024, it raised $189.5 million in net proceeds via a private placement.
- Interest Income: Interest income increased by $3.1 million to $11.5 million, reflecting higher cash balances despite moderate interest rate decreases.
Guidance, Outlook, and Management Commentary
Clinical Progress (NGN-401)
- Phase 1/2 Data: Interim data (cutoff Oct 30, 2025) showed all pediatric participants experienced functional gains, with 35 developmental milestones gained. Four of five participants with 12+ months follow-up met the responder definition for the primary endpoint.
- Embolden Trial (Phase 3): The registrational trial is fully enrolled (20 participants) with >50% dosed. Dosing is expected to complete in Q2 2026.
- Regulatory Designations: NGN-401 received Breakthrough Therapy designation (Feb 2026), RMAT designation (Aug 2024), and PRIME designation (Mar 2025). It is also part of the FDA's START Pilot Program.
- Safety: The 1E15 vg dose has been generally well-tolerated with no cases of hemophagocytic lymphohistiocytosis (HLH). A higher dose (3E15 vg) was discontinued in 2024 following a fatality.
Outlook and Liquidity
- Cash Runway: Management believes existing cash resources ($269.0 million) are sufficient to fund operations through at least Q1 2028.
- Future Capital Needs: The company expects to incur significant losses for the foreseeable future and will require substantial additional capital to advance clinical trials, scale manufacturing, and commercialize products.
- Discontinued Program: The NGN-101 program for CLN5 Batten disease is not being advanced due to the denial of RMAT designation and lack of a streamlined regulatory pathway.
Risks and Contingencies
- Regulatory Uncertainty: Approval processes are lengthy and unpredictable; failure to obtain approval for NGN-401 would materially harm the business.
- Manufacturing Risks: Reliance on in-house manufacturing and third-party suppliers for raw materials poses supply chain risks.
- Legacy Obligations: The company has contingent value rights (CVR) liabilities related to legacy lease and tax obligations from the Neoleukin reverse merger.
Key Facts for Investor Verification
- Cash Position: Verify the $269.0 million cash balance and the accuracy of the Q1 2028 runway projection given the $77.2 million annual cash burn.
- Embolden Trial Status: Confirm the enrollment and dosing progress of the Phase 3 Embolden trial and the timeline for data readout.
- NGN-101 Discontinuation: Assess the financial impact of halting the Batten disease program and the potential for future costs related to patient follow-up.
- Regulatory Milestones: Monitor the FDA's review of the Breakthrough Therapy designation and the alignment on the registrational trial design.
- Stock-Based Compensation: Note the significant increase in stock-based compensation ($14.2 million in 2025 vs. $8.3 million in 2024) and its impact on future dilution.